


# Why IMI matters to Europe's pharmaceutical industry – a PPP success story

Magda Chlebus
Director Science Policy, EFPIA



## Drug development R&D cost vs productivity

European Federation of Pharmaceutical Industries and Associations



Nature Reviews | Drug Discovery



European Federation of Pharmaceutical Industries and Associations



## **European Union and EFPIA CEOs**

joined forces to make

drug development in the EU more innovative and efficient

by

forming the biggest PPP in Life Science

(adopted on December 20, 2007 by the European Council)

10/7/2011





**Innovative Medicines Initiative** 



#### Looking forward

**Combination therapy** 

**Extreme phenotypes** 

**Beyond HTS** 

**Taxonomy** 

Stem cells

EU med info system

Idea generation

Basic Research and non clinical testing

Clinical studies

Regulatory approval

HTA & pharmacovigilance

Knowledge Management infrastructure and services



European Federation of Pharmaceutical Industries and Associations





















surrogate markers for micro- and macro-vascular hard endpoints for innovative diabetes tools













### IMI – the success story

- Proof of concept for new public private collaborations in pharmaceuticals
- Open collaboration to define address common challenges
- A neutral platform for dialogue defining common agenda/priorities
- IMI works: tangible deliverables after less than 2 years – a pace that no other funding scheme allows
- IMI connects the dots between science, health and growth





Thank you!